Skip to main content
Signal8

Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)

$GILDPress releaseJun 2, 2026, 8:30 AM ETRead the release

Gilead reported positive Phase 3 IDEAL trial results for Livdelzi (seladelpar) in primary biliary cholangitis (PBC). The study met its primary endpoint, showing statistically significant composite ALP normalization in patients with inadequately controlled disease (ALP 1-1.67x ULN) compared to placebo after 52 weeks.

Key figures

Drug Name
Livdelzi (seladelpar)
Phase Of Trial
Phase 3
Enrollment
96
Trial name
IDEAL
Duration weeks
52
Primary endpoint
Composite ALP normalization (ALP ≤ 1.0x ULN and ≥ 15% decrease from baseline)
Patient population
PBC patients with ALP 1-1.67x ULN on or intolerant to UDCA

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.